Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626101 | 1.00 | ADRB2 (0.46) | ADRB2GFERALDH1A1CYP3A4TSHR | |
| SCHEMBL1625500 | 1.00 | ADRB2 (0.46) | ADRB2GFERALDH1A1CYP3A4TSHR | |
| SCHEMBL196800 | 0.87 | TAAR1 (0.48) | TSHRTAAR1SLC6A2TRPA1SLC6A3 | |
| SCHEMBL3371824 | 0.81 | ESR1 (0.48) | TSHRTAAR1 | |
| SCHEMBL27585455 | 0.81 | TAAR1 (0.50) | TAAR1SLC6A2LOXL2SLC6A3 | |
| SCHEMBL23586172 | 0.80 | ALDH1A1 (0.50) | ADRB2GFERALDH1A1CYP3A4TSHR | |
| SCHEMBL8985983 | 0.80 | TAAR1 (0.43) | ALDH1A1CYP3A4TDP1TAAR1SLC6A2 | |
| SCHEMBL22591638 | 0.80 | GFER (0.50) | ADRB2GFERALDH1A1CYP3A4TSHR | |
| SCHEMBL9148931 | 0.80 | PTGS1 (0.52) | TSHR | |
| SCHEMBL1336531 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTAAR1SLC6A2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3842420-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-09-05 | — | — | US | disclosed |
| CN-1477960-A | EPA receptor inhibitors to treat rheumatoid arthritis | — | 2004-02-25 | — | — | CN | disclosed |
| CN-1476448-A | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ������ҩ������˾ | 2004-02-18 | — | — | CN | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | ADRB2 184/4885GFER 4489/4885ALDH1A1 588/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | ADRB2 1461/4885GFER 1425/4885ALDH1A1 1858/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ADRB2 412/4885GFER 2160/4885ALDH1A1 1152/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | ADRB2 951/4885GFER 1449/4885ALDH1A1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.